What is Invirsa?
Invirsa is a biotechnology company focused on developing innovative treatments for ocular conditions associated with DNA damage, particularly through their lead compound INV-102. Their primary target clients include patients suffering from ocular injuries due to sulfur mustard gas and those with diabetic dry eye. The company has established a partnership with BARDA to advance the development of INV-102, aiming to provide disease-modifying therapeutic options. Invirsa's strategic approach to drug development addresses significant pharmaceutical challenges in the ocular health sector.
How much funding has Invirsa raised?
Invirsa has raised a total of $10.5M across 2 funding rounds:
Series B
$7.7M
Private Equity
$2.8M
Series B (2023): $7.7M with participation from CincyTech, Rev1 Ventures' Companies, and Jumpstart Ventures
Private Equity (2025): $2.8M, investors not publicly disclosed
Key Investors in Invirsa
CincyTech
CincyTech is a public-private seed-stage investor company specializing in life sciences and digital health, likely providing strategic guidance and capital for Invirsa's early-stage development.
Rev1 Ventures' Companies
Rev1 Ventures is a venture development studio focused on seed-stage venture capital and startup services, indicating a role in accelerating Invirsa's growth and market strategy.
Jumpstart Ventures
Jumpstart Ventures provides learning opportunities and ecosystem connections for young entrepreneurs, suggesting a focus on nurturing Invirsa's innovative approach and team development.
What's next for Invirsa?
With a recent major strategic investment and a total funding amount of $10.5M, Invirsa is poised for significant expansion and advancement of its lead compound, INV-102. The company's focus on ocular conditions linked to DNA damage, coupled with its BARDA partnership, positions it for critical clinical trials and potential market entry. This enterprise-level backing will likely fuel further research and development, scale manufacturing capabilities, and bolster its commercialization strategy, aiming to deliver much-needed disease-modifying treatments to patients suffering from severe ocular ailments.
See full Invirsa company page
